

Novel Non-Leaching Technology is Safe, Highly Effective, and Affordable

NIMBUS® is an FDA-cleared, cutting-edge antimicrobial technology that is custom designed for wound care and medical device applications. It is based on non-toxic, long chain polymers with high charge density that provide superior efficacy via a physical action on microbes. *There are no resistance issues*.

NIMBUS is permanently bound to the wound dressing and will not interfere with wound healing. There are no discoloration issues. NIMBUS is effective against MRSA and VRE and many other pathogens.

NIMBUS technology will enhance the value of your wound care products. It brings dependable, durable and safe antimicrobial protection at extraordinary value—only pennies per product.

Versatile

Absorbent dressings

Adhesives

Foams


Gauze

Hydrogels

Hydrocolloids

Polyurethane films

Non-Leaching • Will Not Cause Bacterial Resistance • Rapid Acting Added Value for Your Product at Extraordinary Low Cost



Proven Effective*

MRSA

VRE

Pseudomonas aeruginosa

Staphylococcus aureus

Escherichia coli

Klebsiella pneumoniae

Proteus vulgaris

Serratia marcescens

Enterococcus faecalis

Enterobacter aerogenes

Listeria monocytogenes

*All tested in 10% bovine serum

You can depend on the safety and efficacy of your product.

NIMBUS technology meets all ISO 10993 /FDA-required biocompatibility and safety standards, including cytotoxicity, primary skin irritation, dermal sensitization and systemic toxicity.



Quick-MedTechnologies, Inc.

NIMBUS® — A Unique Technology

- A broad spectrum antimicrobial
- Highly effective against drug resistant bacteria
- Permanently bonded, non-leaching
- No migration into skin—won't interfere with tissue healing
- Not depleted in use
- Persistent, long lasting effects—lasts for days, weeks, or months
- Large polymer with over 1,500 antimicrobial units per molecule
- Not blocked by organics such as blood, urine, perspiration
- Highly cost effective relative to all competitors
- Will not induce drug resistance
- FDA-cleared

Effective against MRSA & VRE



How NIMBUS works

NIMBUS advanced antimicrobial polymers have high charge density and high molecular weight. They physically disrupt the cell wall of bacteria, working very quickly because of their high charge density. Since the active agent is permanently bonded to the surface, there is no leaching and no depletion of the antimicrobial reservoir. Bacteria cannot develop resistance to an agent that they cannot internalize: the large size of NIMBUS polymers and their permanent attachment to a surface eliminates the ability of microbes to develop resistance.

Highly effective & low cost

Less than 1% the cost of silver and 10% of PHMB

	NIMBUS	Silver	РНМВ	Triclosan	Silane Quat
Effectiveness	High	High	High	Medium	Low
Persistence	High	Medium	Low	Low	Low
Leaching	No	Yes	Yes	Yes	No
Resistance	No	Documented ¹	Documented ^{2,3}	Documented ^{4,5}	No
Economics	***	*	**	**	**

Gupta, A., et al, Nature Medicine 5: 183-188. (1999)

² Moore, L.E., et al, Appl. Environ. Microbiol. 74: 4825-4834 (2008)

Accolades for NIMBUS



"NIMBUS poses no danger of bacteria developing resistance, or of releasing toxic material into the wound and impeding the healing process. It is a novel technology: bonded and effective even in high concentrations of body fluids."

- Gregory Schultz, Ph.D. Professor, Institute for Wound Research University of Florida Past President, Wound Healing Society



TIME Magazine

Innovators Forging the Future Microbe-Busting Bandages March, 2006

> **Wound Healing Society** Blue Ribbon Industrial R&D Award 2006 & 2008



Your next step

Quick-Med Technologies, Inc. 902 NW Fourth Street Gainesville, FL 32601 +1-888-835-2211

Roy Carr

Director, Business Development +1-561-771-1306 rcarr@quickmedtech.com Visit our website at www.quickmedtech.com for further information or contact us by telephone or email.

We provide a range of support including chemistry and formulation development, microbiology testing, regulatory affairs, and manufacturing scale up.

We offer proof of principle per jointly defined test methods to meet your specific performance goals. We then discuss joint development agreements with options for first-to-market licensing.

This document has been prepared to assist in technology evaluation. Data presented herein were collected using standard laboratory methods and are presented solely to substantiate the efficacy of NIMBUS technology. Display of this data is not intended as a public health claim. ©2010, Quick-Med Technologies, Inc.

³ Allen, M.J., et al, *Microbiology* **152**: 989-1000 (2006)

⁴ McIvlurray L.M., et al, Nature 398: 531-532 (1998)

⁵ Heath, R. J., et al, *J. Biol. Chem.* **273**: 30316-30320 (1998)